We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Brachytherapy Optimal for Intermediate-Risk Prostate Cancer

By MedImaging International staff writers
Posted on 14 Jan 2019
Print article
Image: Brachytherapy seeds provide better results for intermediate-risk prostate cancer, according to a new study (Photo courtesy of Alamy).
Image: Brachytherapy seeds provide better results for intermediate-risk prostate cancer, according to a new study (Photo courtesy of Alamy).
A new study reveals that brachytherapy causes less toxicity during treatment of prostate cancer than a combination of brachytherapy plus external beam therapy (EBT).

Researchers at Emory University (Atlanta, GA, USA), Cedars-Sinai Medical Center (Los Angeles, CA, USA), Bon Secours Cancer Institute (Richmond, VA, USA), and other institutions conducted a study to evaluate progression-free survival and patient-reported outcomes in two separate treatment arms, the first treated with partial pelvis brachytherapy alone, and the second treated with a combination of brachytherapy + EBT.

Men with prostate carcinoma were randomly assigned to one of the treatment arms; the researchers then measured changes from baseline to four and 24 months using expanded prostate index composite (EPIC) score and three prostate cancer-specific patient-reported outcome domains (bowel, urinary, and sexual). The results showed that at 24 months the men on the brachytherapy + EBT arm reported poorer urinary, bowel, and sexual patient-reported outcomes and much greater toxicities (13%) than the brachytherapy alone arm (7%).

In addition, the researchers found that toxicity, the major symptom of concern, was underreported by clinicians, compared to patient reports. The clinicians reported late grade 3 bladder or genitourinary toxicities of 8% for the brachytherapy + EBT arm, and 3% for the brachytherapy alone arm, compared to the patients, who reported 34% bladder or genitourinary toxicities for brachytherapy + EBT and 23% for brachytherapy alone. The study was presented at the American Society for Radiation Oncology (ASTRO) annual meeting, held during October 2018 in San Antonio (TX, USA).

“Although progression-free survival was similar on both treatment arms, the addition of external-beam therapy yielded a higher percentage of clinician-reported late grade 3 or greater toxicities,” concluded lead author and study presenter Deborah Bruner, RN, PhD, of Emory University. “Patient-reported data confirms that brachytherapy alone is the superior treatment for men with intermediate risk prostate cancer, with less patient-reported side effects. Brachytherapy alone would also be the most cost-efficient treatment option for patients.”

Brachytherapy is a radiotherapy regimen in which a radioactive source is placed directly into or next to an organ or tissue. In the case of prostate cancer, two main types of brachytherapy are available. Low dose rate (LDR) brachytherapy involves the insertion of permanent radioactive sources (seeds) directly into the prostate, which release localized radiation to the entire prostate with the aim of destroying the cancer cells. (HDR) brachytherapy also involves radioactive material being placed directly into the prostate but for shorter periods, usually for a day or two at a time, and usually in conjunction with EBT.

Related Links:
Emory University
Cedars-Sinai Medical Center
Bon Secours Cancer Institute

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Digital Radiography Acquisition Software
VXvue with PureImpact
Mammography System
MAMMOVISTA B.smart
New
DR Flat Panel Detector
1500L

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.